Ultime notizie per Redfin (NASDAQ:RDFN) Azioni

REDFIN CORP

Redfin

Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments real estate services, rentals, mortgage, title, and monetization. The company generates the majority of its revenue from Real estate services.

10 Stocks Jim Cramer Says Will Thrive Despite Trump’s Tariffs

News

Markets

Media

Trading Ideas

PLTR

RDFN

SHOP

SOUN

Un&#39;analisi approfondita delle raccomandazioni del conduttore di &#39;Mad Money&#39; e delle possibili opportunità offerte dal mercato finanziario.

Jim Cramer: ecco i titoli da comprare e vendere - L&#39;analisi completa

Why Warren Buffett Turns To Kipling’s 1895 Poem “If—” When Markets Crash

La possibile cessione a Compass Real Estate è un segnale di sfiducia nel mercato o una mossa strategica per puntare sulla proptech?

La scommessa di Buffett sul futuro dell&#39;immobiliare: cosa c&#39;è da sapere

Redfin Corp

Baird analyst Andrew Wittmann maintains UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) with a Neutral and lowers the price target from $218 to $197.

Price Target

Analyst Ratings

Baird Maintains Neutral on UniFirst, Lowers Price Target to $197

Fort Lauderdale, FL, April 03, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=V-0nYzFaL2nHiXE8MQvul89eQUpKHI9mbKvadvKCrHeI2_s5h3R-RL4gPhAxDulc0wsznXaWrBuUjiN3QO0nDT6_i9uEokQLL5Vm6VDJIkA=">MARA Holdings, Inc.</a> (NASDAQ: <a href="https://www.globenewswire.com/Tracker?data=hgFvAausj0i1ZfS9Vgw1tw_AYTQ5E6eBzO7be50lW9S1iouX4Mod6HQjZluQpJyctURoTeOcW39mQ0ZH1oR07A==">MARA</a>) ("MARA" or the "Company"), a global leader in leveraging digital asset compute to support energy transformation, today published unaudited bitcoin ("bitcoin" or "BTC") production updates for March 2025.
Management Commentary "In March, our production saw a 17% month-over-month increase in blocks won, even as global hashrate and mining difficulty grew," said Fred Thiel, MARA's chairman and CEO. "Our bitcoin holdings surpassed 47,000 BTC during March and the 242 blocks mined were the third most in a month on record.
"MARAPool is the only self-owned and operated mining pool among public miners, offering distinctive control and efficiency. Operating our own pool means no fees to external operators, higher earnings and superior performance. MARA Pool's luck factor has exceeded the network average by over 10% since launch, meaning more blocks mined and higher rewards.
"Energized hashrate grew 1% over February and we expect to finish construction of our 40-megawatt data center in Ohio by the end of April. We will continue to focus on being the dominant player in bitcoin mining while expanding our footprint in energy generation."

MARA

MARA Announces Bitcoin Production And Mining Operation Updates For March 2025; Company Won 242 Blocks, A 17% Increase MoM. Increased Bitcoin Holdings To 47,531 BTC

Baird analyst Andrew Wittmann maintains Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) with a Neutral and lowers the price target from $46 to $43.

Baird Maintains Neutral on Fluor, Lowers Price Target to $43

General

NRXP

NRX Pharmaceuticals' HOPE Therapeutics Signs Term Sheet With A Global Medical Device Manufacturer; The Term Sheet Contemplates An Investment Of $2.5M To Purchase Series A Convertible Preferred Stock At $50M Pre-Money Valuation

CASI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>, ", CASI", ))), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that its special committee of the board of directors (the "Special Committee") has received an updated preliminary non-binding proposal letter (the "Proposal Letter"), dated April 2, 2025, from Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company, to acquire the entire business operations of the Company in China and all license-in, distribution and related rights in Asia (excluding Japan) related to certain pipeline products of the Company, including BI-1206, CID-103 and Thiotepa, for an aggregate purchase price of $20.0 million, which shall include assumption of approximately $20.0 million of indebtedness of the Company (the "Proposed Transaction").
The Proposal Letter updates the preliminary non-binding proposal letter submitted by Dr. He to the Company on June 21, 2024. The Proposal Letter conveys Dr. He's intent to make certain adjustment to the scope of, and considerations for, the pipeline products involved in the Proposed Transaction based on latest information disclosed by the Company.
As previously announced, the board of directors of the Company had formed the Special Committee to evaluate the Proposed Transaction, or any alternative strategic option that the Company may pursue. The Special Committee will continue to evaluate the Proposed Transaction in light of the latest development.

CASI

CASI Pharmaceuticals Receives Updated $20M Proposal From CEO Dr. Wei-Wu He To Acquire Co's Business Operations In China And Asian Rights To Certain Pipeline Products, With Special Committee Continuing Evaluation Of The Proposed Transaction And Strategic Alternatives

Baird analyst Peter Benedict maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Neutral and lowers the price target from $400 to $215.

Baird Maintains Neutral on RH, Lowers Price Target to $215

The AI revolution isn&#8217;t just about chips—it&#8217;s about the high-speed highways that move data between them. According to JPMorgan analyst Harlan Sur, Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) are at the center of this networking build-out, making them prime beneficiaries of <a href="https://www.benzinga.com/topic/artificial-intelligence">the AI boom</a>.
<h2 class="wp-block-heading">Networking Demand Surges with AI Compute</h2>
Sur highlights that the rapid expansion of accelerated computing &#8211; powered by Nvidia Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Blackwell GPUs, Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google&#8217;s TPUv6, and Amazon.com Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Trainium 2 &#8211; is fueling an insatiable need for faster networking. As hyperscalers scale out their data centers, demand for 800G and next-gen 1.6T networking solutions is set to soar through 2025 and beyond.
At the OFC Networking Conference this week, Broadcom showcased its dominance in high-performance switching, with its Tomahawk 5 and Jericho 3 chipsets seeing strong demand. The company is also gearing up for the launch of its 3nm Tomahawk 6 later this year, further strengthening its AI networking footprint.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/44588724/intel-make-or-break-moment-can-new-ceo-lip-bu-tan-turn-it-around">Intel Faces Make-Or-Break Moment: Can New CEO Lip-Bu Tan Turn It Around?</a>
<h2 class="wp-block-heading">Marvell: The King Of PAM4 DSPs</h2>
Marvell continues to dominate the PAM4 DSP market, commanding over 70% market share and generating more than $1.5 billion in revenue from this segment in 2024. 
The company is leading the charge in next-gen 1.6T AEC and silicon photonics (SiPho) solutions, positioning itself to capitalize on both scale-out and scale-up networking demand. With strong AI-ASIC ramps in the pipeline, Marvell's data center business looks set for solid Q/Q growth through the rest of the year, the analyst said.
<h2 class="wp-block-heading">Broadcom: The Networking Powerhouse</h2>
Broadcom, meanwhile, is flexing its dominance in high-performance networking. Its Tomahawk 5 switch (51.2Tbps throughput) is already in high-volume production, and the next-gen Tomahawk 6 (102Tbps) is expected to drop later this year. AI-related networking revenue is up over 60%, and Broadcom's deep lineup of scale-out and scale-up solutions—ranging from PCIe Gen5 connectivity to co-packaged optics—keeps it ahead of the pack, according to Sur.
<h2 class="wp-block-heading">Actionable ETFs for Investors</h2>
For those looking to gain exposure to this AI-driven networking surge, iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) and VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) both hold significant positions in Broadcom and Marvell, making them prime ways to ride this wave.
With hyperscalers racing to upgrade their AI infrastructure, Broadcom and Marvell are sitting in the sweet spot. 
With demand for ultra-high-speed networking solutions on the rise, these two semiconductor leaders appear well-positioned for further growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44539735/nvidia-stock-an-attractive-opportunity-analyst-says-valuation-cheap-despite-china-restrictions">Nvidia Stock &#8216;An Attractive Opportunity,&#8217; Analyst Says Valuation Cheap Despite China Restrictions</a></li>
</ul>
Photo: asharkyu/Shutterstock.com

Analyst Color

Long Ideas

Tech

AMZN

AVGO

GOOG

GOOGL

MRVL

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

JPMorgan Says Broadcom, Marvell Could Dominate AI's Next Frontier — Here's Why

<a href="https://www.globenewswire.com/Tracker?data=7l57jPT7AZDn06CKZpFEvCZWIfVofhoCdY1ADg0wIzox9VuZpgQRe1PjoOSmOEVcGBL6lOiOros8Dh9aXF-XJoIVl6t6ZeONjLprU1SgmlU=">Akebia Therapeutics&#xAE;, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL&#xAE; (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Averoa, a renal-focused biopharmaceutical company, licensed the rights to develop and commercialize ferric citrate from Akebia in the European Economic Area and certain countries in Europe and the Middle East. Averoa recently announced the positive opinion from CHMP here: <a href="https://www.globenewswire.com/Tracker?data=YC3k_S4HYmByvgOHZ8KXr9C0l6cq2mm2kfWvZCIPt6Z_Lb_YAZuD_AN4OU8B8GfuKWmJWYc1ze_64nltBee9vEAkzlG0WPcS8tWwIQOgbg6vFL0aZwl9rFqnbqLk1eJ21wf7V3RWjz3kl4lrcqqsJ0FtpBJzHBRGq2fXfRng6WWEcZJcsByl-xY1MSoTfuiY4IfFo9KwQezWnnOVW2ZRKUgDbA9JFoMZh9bfpbTLWnRCZsioMOIoCuyDeRr2FdWMyD4-vYX-cKnW8l08ViedE5-LMOEdXv0Fd-LS6zelN-AJTu2nE1ZtTq8h_35h_TKX">https://averoa-pharma.org/wp-content/uploads/2025/04/20250402-AVA1014-Positive-opinion-EN-VF-2.04.2025.pdf</a>.
"We congratulate our partner Averoa on a positive step toward securing EMA approval for XOANACYL, and we will continue to support their efforts to deliver a treatment for complications of kidney disease to patients in Europe," said John P. Butler, Chief Executive Officer of Akebia.
The EC will review the CHMP recommendation, and a final decision is expected in approximately two months.

Biotech

AKBA

Akebia Therapeutics Announces Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted A Positive Opinion Recommending The European Commission To Approve Xoanacyl For Treatment Of Concomitant Elevated Serum Phosphorous And Iron Deficiency In Adult Patients With Chronic Kidney Disease

Auralink AI processed $1.2M in billed switching activity in March 2025 (based on internal system data)
CallAI&#x2122; integration expected to enhance efficiency through AI-based call automation and routing
Infrastructure scaling and AI talent expansion underway to support platform growth
NEW YORK, NY / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 3, 2025 / Nixxy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>), or Nixxy, or the Company, today announced preliminary operational metrics for its Auralink AI subsidiary, highlighting internal system activity and progress toward broader platform readiness. In March 2025, Auralink AI processed approximately $1.2M in switching and billing activity, based on internal usage data and system modeling. Final revenue recognition will be determined in accordance with applicable accounting standards. Based on the higher-than-expected revenue, Nixxy will be reviewing April forecasts and revising them accordingly in the near future.

NIXX

Nixxy Issues Operational Milestone Update And Highlights AI Integration Progress; Auralink AI Processed $1.2M In Billed Switching Activity In March 2025

Focus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US 1 impacted by these conditions and opens new opportunities for GeneDx and biopharma partners to accelerate the path to treatment for patients

GeneDx Expands Commercial Expansion Into Inborn Errors Of Immunity

Total Consideration Including CVR Represents Up to Approximately 80% Premium Over MoneyLion's 60-day VWAP1
Leading Proxy Adviser Glass Lewis Recommends Stockholders Vote FOR Transaction
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmlion.info%2F4c9tYeA&amp;esheet=54232930&amp;newsitemid=20250402433600&amp;lan=en-US&amp;anchor=MoneyLion&amp;index=1&amp;md5=4433dcc9150b5d90ad5e0bc5251e65ef">MoneyLion</a> ("MoneyLion") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) today issued the following letter to shareholders regarding its proposed acquisition by Gen Digital Inc. ("Gen") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>):
April 3, 2025
Dear Fellow Shareholders,
On Thursday April 10, 2025, we will hold our Special Meeting of Shareholders to vote on the proposed merger with Gen Digital Inc. ("Gen"). Ahead of the meeting, we want to reaffirm the compelling value of the transaction, and why it represents the best path forward for MoneyLion and our shareholders.
As you know, the transaction offers a total consideration of up to approximately $110 per share1, which represents an up to 80% premium over MoneyLion's unaffected 60-day volume-weighted average share price ("VWAP"). The total consideration comprises:
<ul>
<li>Immediate payment of $82.00 per share in cash at closing, which represents a premium of approximately 9.5% over our unaffected 30-day VWAP, 33.5% over our unaffected 60-day VWAP, and 46.8% over our unaffected 90-day VWAP2; and</li>
<li>One contingent value right ("CVR") for each share owned that entitles the holder to a contingent payment of 0.7546 shares of Gen common stock, representing an additional $23.00 of value based on the trading price of Gen shares at the time of entry into the merger agreement and an additional $28.30 of value if the CVR milestone is met.3&nbsp;</li>
</ul>
Your Board competitively negotiated this transaction on behalf of our shareholders, during which process we were able to increase the final consideration by 84%-92% relative to Gen's initial proposal of $51.00-$52.00 per share.4 We also negotiated a robust go-shop process, and following announcement our financial advisors actively reached out to 36 potential acquirors. While several parties signed non-disclosure agreements - and two parties engaged in management meetings with MoneyLion - ultimately no other party submitted a superior proposal.
By joining forces with Gen, we will create a full-featured personal finance platform that builds on Gen's identity solutions by offering comprehensive financial wellness and driving significant growth potential. The transaction with Gen is the clear and best path forward to maximize value for your investment, offering compelling and immediate cash value with the opportunity to benefit from the substantial upside of the CVR or to sell the CVR, which is expected to be listed on Nasdaq, and realize additional immediate cash proceeds.
The Board strongly believes this transaction is superior to MoneyLion continuing as a standalone company, especially in light of recent significant market volatility and ongoing macro uncertainty, which has particularly impacted the financial technology sector.
A recent report published by leading proxy advisory firm, Glass Lewis, agrees with our Board's determination in its recommendation that shareholders vote FOR the transaction with Gen

MoneyLion Reaffirms Proposed Acquisition By Gen Digital, Offering Total Consideration Of Up To $110 Per Share

KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=QMke-mCOpJ57BCQhaqP470QE49XHOsoDxxKgk_gJil_hz2XsFiRt4AaIg3c7adFAINFxMFndV-4ZR2JM0vyvqPdrOEQKATl95Dy7lH8_C7S4ikVBtdRrPfTk4ZTvUYg_Y_BRnke4OWCWiJ3sH3-HdWlmCRt7UyMXpGb6XST0ph7ety2rlRMl-ZRC_jeubGy1Fj1guNI77NTu3pq19ykVXOBUJmoObiah8ZcJ7XRbksIkJDhOIwfcts5LX4DGbkYKJwxtnucR0T59__7yf5PofQGirB9tJcU5VSQLpZf1L81n3FyiyevjAQ1MtQByWXIFKjEb2Jpqgxxq7xgsl7RFGOTa8v9f_ajbGQQSoGjLdCz1SBAbUl4krn0Obo627oGH7P6CAxMoBRy3bdb6I2Ucj428Av7GLluherh3ZwdgOp9AAI9SmtpC68nVjSINvqjVAGq3L4bEDkeTJA0XlamKVKxTE9Zv4mBE5VG3GFrtJqU7k8yRCthhVE3TxXoduAoOe8YPtVgO7FWK5-1tNYvOW0jmzm4GzmcwgV7tqWohjlqD714N2IDT5qB9L7ApBTKFGr0PdIll22tE2_Nbgy24Y6Fy5dwq-8baUT5QsosKL2HVbT1ZnXxV3fIBcZatRH8OqGZMbnOIqenYTHGa38iUDym6Qs19ZyrO2b9qCvgRHZo=">Cingulate Inc.</a>&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>), a biopharmaceutical company utilizing its proprietary Precision Timed Release&#x2122; (PTR&#x2122;) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it held a Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) yesterday to discuss the submission of a new drug application (NDA) for its lead Phase 3 asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).
"Our meeting with the FDA yesterday was very productive, and we remain on track for an NDA filing of CTx-1301 in mid-2025. We truly appreciate the FDA personnel who have been involved with the regulatory review of CTx-1301 to date. These interactions have been essential in helping us generate data to demonstrate the consistency and therapeutic benefit of our product. This important milestone is validation of our mission to bring to market the first, true, once-daily stimulant medication to treat ADHD over the entire active day," said Cingulate Chairman and CEO Shane J Schaffer.
Last month Cingulate released Phase 3 safety data for CTx-1301, as well as the results from a food effect study with healthy adults, using a single 50-mg dose of CTx-1301, Cingulate's highest dosage. A review of the results found that the safety profile of CTx-1301 has remained consistent over the course of nine clinical trials. A final analysis that combines both adult and pediatric safety and efficacy data will be prepared and included in the NDA submission.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

CING

Cingulate Announces Pre-NDA Meeting With FDA For Discussion Of New Drug Application For Lead ADHD Asset CTx-1301

PO Sync allows merchants to put replenishment on auto-pilot with a fully-integrated, trail-blazing wholesale network that redefines and simplifies the buying process for retailers and brands across the globe. &nbsp;
MONTREAL, April 3, 2025 /PRNewswire/ -&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4397861-1&amp;h=4128617570&amp;u=https%3A%2F%2Fwww.lightspeedhq.com%2F&amp;a=Lightspeed+Commerce+Inc.">Lightspeed Commerce Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#TSX">LSPD</a>) ("Lightspeed" or the "Company"), the one-stop commerce platform empowering merchants to provide the best omnichannel experiences, today unveils Inventory Replenishment directly integrated into Lightspeed Retail, the premiere Point of Sale for ambitious retailers. Tapping into Lightspeed NuORDER, this launch introduces capabilities to streamline wholesale processes for leading brands and retailers, including a new, rebranded name for Lightspeed's wholesale network.
PO Sync allows retailers to place order replenishments within Lightspeed's POS platform and send to their suppliers in one click. This takes a process that is manual, time-intensive and repetitive and makes it automated and data-driven, helping retailers put replenishment on auto-pilot.
PO Sync is the latest enhancement from Lightspeed as part of Lightspeed NuORDER.
Lightspeed NuORDER, brings together over 4,000 brands with 100,000+ retailers as part of a wholesale network that is transforming how retailers and suppliers do wholesale commerce. Through product and brand discovery, automated ordering and replenishment and access to industry and sell through insights, both retailers and brands experience a wholesale partnership that's more profitable, data-driven and can be managed in less time with less steps making it easier for both brands and retailers to grow their business.

LSPD

TSX:LSPD

Lightspeed Commerce Launches PO Sync, Simplifying Wholesale Ordering And Automating The Replenishment Process Through Lightspeed Retail And NuORDER Network, Empowering Merchants With Data-Driven, Time-Saving Solutions

RESTON, Va., April 3, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4395237-1&amp;h=847953387&amp;u=https%3A%2F%2Fwww.leidos.com%2F&amp;a=Leidos">Leidos</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) today announced a new contract to provide signals intelligence (SIGINT) capabilities, engineering, analysis and reporting tools to the National Security Agency (NSA). The base year plus four option years single-award contract has a ceiling value of $390 million.
Leidos will perform a wide range of technical, engineering, systems administration and management functions. Tasks include delivery of SIGINT capabilities, analysis and reporting tool modifications, engineering services, lab and testbed management, integration and testing, deployment, training, and sustainment of a subset of NSA systems.
"Tailored and unique SIGINT solutions for the military and intelligence community are critical to delivering information superiority at speed," said Roy Stevens, Leidos National Security Sector president. "This contract will leverage Leidos' engineering and technical expertise, as we expand our work with the NSA."
Leidos combines expertise in cyber and IT managed services, as well as radar, sensors and other technologies, to develop SIGINT technologies, with end-users always in mind. Those technologies include resilient communications that operate through interruption to keep critical mission data flowing.

Contracts

LDOS

Leidos Receives $390M NSA Signals Intelligence Contract

Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) (the "Company"), a global leader in e-commerce for technology products, today announced that the twenty-to-one share combination (commonly referred to as a reverse stock split) of its common shares will become effective on April 7, 2025 upon the filing of the Amended and Restated Memorandum and Articles of Association with the Registry of Corporate Affairs in the British Virgin Islands, which will result in a proportionate increase to the par value of the Company's common shares from $0.021848 per share to $0.43696 per share. As previously announced, the share combination was approved by the Company's board of directors and the controlling shareholders of the Company by written consent. While the CUSIP number for the Company's common shares will change from G6483G 100 to G6483G 209, the common shares will continue to trade on the Nasdaq Capital Market under the symbol "NEGG." The share combination is intended to enable the Company to continue to meet minimum Nasdaq listing price per share requirements and will affect all shareholders proportionately. The share combination will not alter any shareholder's percentage interest in the Company, except for fractional shares created by the share combination, which will be exchanged for cash.
The Company's transfer agent, Computershare Inc. ("Computershare"), is acting as the exchange and paying agent for the share combination. Registered holders are encouraged to contact Computershare and beneficial holders are encouraged to contact their bank, broker or other nominee with any questions.

Stock Split

NEGG

Newegg Commerce Announces 20-For-1 Reverse Stock Split Effective April 7, 2025

VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) (FSE: 49Q) (BMV:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#BMV">ZENA</a>) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone-as-a-Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces that it has closed the acquisition of Wallace Surveying Corporation ("Wallace") of West Palm Beach, Florida, a well-established land survey company with thirty years of experience. Wallace provides construction and land development surveys delivering accurate and reliable data that supports project planning and design for developers, contractors, engineers, and architect customers.
This is ZenaTech's second acquisition in the Southeast region as part of a larger national roll-up strategy to disrupt the land survey industry by accelerating the use of drones for speed and accuracy benefits. The acquisition also further powers the Company's national Drone as a Service, or DaaS, business as the third US acquisition set to provide access to the ZenaDrone 1000 and the IQ series. These multifunction drones are set to provide a variety of services including power line inspections, precision agriculture, law enforcement, and search and rescue for natural disasters such as hurricanes.
"Wallace Surveying Corporation is well respected in the South Florida business community with longstanding existing customer relationships. Its team brings considerable expertise toward our goal of innovating land surveys at scale leveraging advanced drone data collection, data management, mapping and digital deliverables. This acquisition is another step towards our vision to create a national DaaS business, bringing AI drone efficiencies and precision to a variety of legacy verticals and manual tasks," said CEO Shaun Passley, Ph.D.
ZenaTech's Drones as a Service or DaaS model is similar to Software as a Service (SaaS), but instead of providing software solutions over the Internet, the company will offer ZenaDrone solutions and services on a subscription or pay-per-use basis. Customers can conveniently access drones for eliminating manual or time-consuming tasks achieving more precision, such as for surveying, inspections, security and law enforcement, or farming precision agriculture applications, without having to buy, operate, or maintain the drones themselves.
The DaaS business model offers customers such as government agencies, real estate developers, construction firms, farmers or energy companies reduced upfront costs as there is no need to purchase expensive drones, as well as convenience, as there is no need to manage maintenance and operation. The model also offers scalability to use more often or less often based on business needs and enables access to advanced drone technology sensors or attachments like spraying, without the need for specialized training.
Accurate land surveys are essential for the planning, designing, and executing of roads, bridges, and building projects for cities, commercial, and residential projects, and are required for legal purposes. Remotely piloted drones with an array of sensors and cameras, LiDAR (Light Detection and Ranging), and GPS systems for capturing high-resolution pictures and data are revolutionizing the land survey industry gathering aerial data across expansive terrains in a matter of hours instead of weeks or months using more traditional photogrammetry methods.
According to <a href="https://www.globenewswire.com/Tracker?data=miePsDL-_0-Ay_GO6mmTWFtiQ22U5GrrPlJlQ_3uafN9VuNFYYlwXlFDVfKCSgO37-ZOC93jy6ThGS6N2Oqw4IOSWjPWkkBGznF3Q--wPszcCBiUw1rZquVRFH4YYpZW">Fact.MR</a>, the global drone surveying market is poised for substantial growth and is expected to be worth over USD $8 billion globally by 2030. This market is expanding at a CAGR of 15-20%, driven by increasing demand from industries such as construction, agriculture, and infrastructure development. In particular

BMV:ZENA

ZENA

ZenaTech Achieves Second Southeast Region Acquisition, Wallace Surveying Corporation, To Become Third Acquisition To Power Its National Drone As A Service Business

PCRX

Pacira BioSciences Announces Dosing Of First Patient In Phase 2 Study Assessing Safety And Efficacy Of PCRX-201 For Knee Osteoarthritis Treatment

<ul>
<li>CREXONT added to 3 large national formularies: Veterans Administration, UnitedHealthcare and CVS Health</li>
<li>Increases insurance coverage to over 50% of covered lives</li>
<li>CREXONT was approved by the U.S. FDA to treat Parkinson's disease in 2024</li>
</ul>
Amneal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that three large insurance coverage accounts, the Veterans Administration (VA), UnitedHealthcare and CVS Health, have added CREXONT&#xAE; (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson's disease (PD) to their national prescription drug formularies. CREXONT is a prescription medication for the treatment of PD approved by the U.S. FDA in August 2024.
This expanded coverage increases CREXONT's total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50%. The Company had initially set a goal to surpass 50% coverage by the end of 2025, making this milestone—achieved nine months ahead of schedule—a testament to Amneal's commitment to broadening patient access. The VA has already added the product in its national formulary, covering approximately 10% of U.S. PD patients. UnitedHealthcare will add CREXONT to its standard prescription drug lists in the second quarter of 2025. In addition, CVS Health will add CREXONT as a "preferred" product to its national formulary on July 1, 2025.

AMRX

Amneal Announces Expanded Coverage For CREXONT To Enhance Access For Parkinson's Disease Patients In The U.S.; Increases Insurance Coverage To Over 50% Of Covered Lives

Gencor Industries, Inc. (the "Company" or "Gencor") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENC#NYSE">GENC</a>) previously reported that it needed additional time to complete its audit of the Annual Report on Form 10-K for the year-end September 30, 2024. In connection with this delay, the Company filed a Form 12b-25 with the Securities and Exchange Commission with respect to the Company's Annual Report on Form 10-K for the year-end September 30, 2024. The Company similarly filed a Form 12b-25 with the Securities and Exchange Commission with respect to its Quarterly Report on Form 10-Q for the period ended December 31, 2024.
Unaudited Preliminary Results:
Set forth below are select unaudited preliminary estimates of operating results for the fiscal 2025 first quarter ended December 31, 2024 and cash and marketable securities and backlog at March 31, 2025.
The Company anticipates reporting revenue of approximately $31 million for the first quarter of fiscal 2025, compared to $26 million for the first quarter of fiscal 2024.
At March 31, 2025, the Company had approximately $144 million in cash and marketable securities, compared with approximately $117 million at March 31, 2024, with no short-term or long-term debt.
The Company's backlog at March 31, 2025 was approximately $24 million.

Guidance

GENC

Gencor Preliminary Q1 Revenue Of ~$31M Up From $26M YoY

<ul>
<li>On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)</li>
<li>U.S. FDA BLA submission for accelerated approval planned for 2H 2025</li>
</ul>
BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN).
"We are grateful for the IgAN community's strong interest in the clinical development of atacicept that helped drive us towards completing full enrollment in the ORIGIN 3 trial with a total of 431 participants. Complete enrollment represents another key milestone on the path to potential approval of the first B cell modulator targeting both BAFF and APRIL for IgAN," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "We anticipate the 36-week primary efficacy endpoint data from the trial this quarter, which supports our planned Biologics License Application for an accelerated approval to the U.S. FDA in the second half of 2025. ORIGIN 3 follows the positive long-term results from the ORIGIN Phase 2b trial that demonstrated sustained and substantial reductions in Gd-IgA1, hematuria and proteinuria, and showed stabilized kidney function through 96 weeks, positioning atacicept as a potential best-in-class IgAN therapy. Pending the submission and thorough FDA review of the BLA, we would look forward to a potential PDUFA date and commercial launch in 2026."
The ORIGIN 3 trial (NCT04716231) is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of atacicept in patients with IgAN who have persistent proteinuria and remain at high risk of disease progression. Participants are randomized 1:1 to at-home self-administered once-weekly subcutaneous injections of atacicept 150 mg or placebo for a 104-week double-blind period, followed by a 52-week open-label extension.
The primary efficacy endpoint is the change in proteinuria as evaluated by urine protein to creatinine ratio (UPCR) through 36 weeks in an interim analysis of at least 200 participants. The key secondary efficacy endpoint is change in kidney function as measured by estimated glomerular filtration rate (eGFR) through 104 weeks in the full study population.

VERA

Vera Therapeutics Announces Full Enrollment In ORIGIN Phase 3 Trial For Atacicept In IgAN

Press Releases

Redfin Reports Home Sales Dropped Significantly in Altadena and the Pacific Palisades in Aftermath of Los Angeles Wildfires

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, AMPS, ML, WBA on Behalf of Shareholders

Redfin Reports Monthly Housing Payments Hit All-Time High

New York and the Midwest Dominate Redfin's Hottest Neighborhoods of 2025

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, RDFN, AMPY, HEES on Behalf of Shareholders

Big City Comeback: Homebuyer Competition Is Rising Fastest in the Bay Area, New York

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HMST, COOP, OPTN, RDFN on Behalf of Shareholders

Redfin Publishes 2025 Industry Survey

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, RDFN, ALLK on Behalf of Shareholders

Redfin Reports Spring Brings Record-High Monthly Housing Costs, Keeping Pending Home Sales at Bay

ALLK

AMPS

AMPY

COOP

HEES

HMST

OPTN

TURN

Altisource Portfolio Solutions S.A. - Common Stock

Altisource Portfolio

KE Holdings Inc American Depositary Shares (each representing three Class A Ordinary Shares)

Comments

Redfin

Notizie

Ultime notizie per Redfin (NASDAQ:RDFN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO